Methods of treating Fabry disease in patients having a mutation in the GLA gene
Summary
USPTO granted Amicus Therapeutics Patent No. US12594268B2 covering methods of treating Fabry disease using pharmacological chaperones for α-galactosidase A in patients with GLA gene mutations. The patent includes 9 claims and was filed on January 16, 2019. This IP protection grants Amicus Therapeutics exclusive rights to these therapeutic methods for the rare genetic disorder.
What changed
The USPTO has formally granted Amicus Therapeutics a new patent covering methods of treating Fabry disease by administering pharmacological chaperones for α-galactosidase A to patients carrying GLA gene mutations. The patent comprises 9 claims and was issued on April 7, 2026. This patent grant provides Amicus Therapeutics with enforceable intellectual property rights that may restrict competitors from developing or commercializing similar therapeutic approaches for Fabry disease treatment.
Pharmaceutical companies developing treatments for rare genetic diseases, researchers in enzyme replacement therapies, and investors in Fabry disease therapeutics should assess how this patent affects their freedom to operate or product development strategies. Healthcare providers treating Fabry patients may benefit from understanding which therapeutic approaches are now protected intellectual property.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating Fabry disease in patients having a mutation in the GLA gene
Grant US12594268B2 Kind: B2 Apr 07, 2026
Assignee
Amicus Therapeutics, Inc.
Inventors
Elfrida Benjamin
Abstract
Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
CPC Classifications
A61K 31/445 A61P 3/00
Filing Date
2019-01-16
Application No.
17269890
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.